| P50 | author | Tomáš Zima | Q12059354 |
| | Marta Kalousová | Q42807160 |
| | Petra Tesařová | Q62523814 |
| | Karel Zvára | Q83856895 |
| | Marie Jáchymová | Q114340128 |
| | Alexandra Moravská | Q114340130 |
| P2093 | author name string | Anna Germanová | |
| P2860 | cites work | The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life | Q24527362 |
| | Glyoxalase I--structure, function and a critical role in the enzymatic defence against glycation | Q28187673 |
| | Expression of glyoxalase I and II in normal and breast cancer tissues | Q28190025 |
| | Glyoxalase activities in tumor and non-tumor human urogenital tissues | Q28291065 |
| | N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression | Q28645594 |
| | A possible regulatory role of 17beta-estradiol and tamoxifen on glyoxalase I and glyoxalase II genes expression in MCF7 and BT20 human breast cancer cells. | Q30803694 |
| | Glyoxalase I phenotype as a potential risk factor for prostate carcinoma | Q31866973 |
| | Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer | Q33220463 |
| | Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage-derived cell lines | Q34393482 |
| | Alpha-oxoaldehyde metabolism and diabetic complications | Q35594284 |
| | Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy | Q35594294 |
| | Oxidative DNA damage and disease: induction, repair and significance | Q35876708 |
| | Alterations of mitochondrial DNA in common diseases and disease states: aging, neurodegeneration, heart failure, diabetes, and cancer | Q36048239 |
| | Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. | Q36220722 |
| | Reversal of anticancer drug resistance by COTC based on intracellular glutathione and glyoxalase I. | Q40462790 |
| | Increased incidence of neoplasia in chronic renal failure (20-year experience). | Q43966014 |
| | Selenium level and glutathione-dependent enzyme activities in normal and neoplastic human lung tissues | Q44159129 |
| | The characterisation and functional analysis of the human glyoxalase-1 gene using methods of bioinformatics | Q45099100 |
| | Common polymorphisms in the glyoxalase-1 gene and their association with pro-thrombotic factors | Q46817492 |
| | Association analysis of the functional Ala111Glu polymorphism of the glyoxalase I gene in panic disorder | Q46849604 |
| | AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept | Q47864019 |
| | The human red blood cell glyoxalase system in diabetes mellitus. | Q53887937 |
| | Endogenous secretory receptor for advanced glycation end products in non-small cell lung carcinoma. | Q54577822 |
| | Receptor for Advanced Glycation End Products (RAGE)—Soluble Form (sRAGE) and Gene Polymorphisms in Patients with Breast Cancer | Q57825328 |
| P433 | issue | 6 | |
| P304 | page(s) | 655-660 | |
| P577 | publication date | 2009-07-01 | |
| P1433 | published in | Cancer Investigation | Q325953 |
| P1476 | title | Glyoxalase I Glu111Ala polymorphism in patients with breast cancer | |
| P478 | volume | 27 | |